Melinda Gooderham, MD, MSc, FRCPC, Peterborough Regional Health Centre in Ontario, Canada, discusses recent trials and studies that have been conducted on emerging therapies for patients with atopic dermatitis.
For a patient population with very sensitive skin, having a well-tolerated therapy is extremely important, says Melinda Gooderham, MD, MSc, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre in Ontario, Canada.
Transcript
How do emerging therapies work to address the underlying causes of atopic dermatitis?
These emerging therapies can be more targeted, such as interleukin-13, which we know is a key cytokine in the pathophysiology of atopic dermatitis. We can block with nemolizumab interleukin-31 which is a key itch cytokine in atopic dermatitis causing the most burdensome symptom for our patients.
To have those targeted therapies that block either the inflammation or the itch that's leading to the impairment of quality of life of our patients in a safe way, I think, is a win-win situation—to have the efficacy along with the safety.
For the topicals, they are not quite as targeted. They are blocking, usually, cell signaling, in some sense, to reduce inflammation, reduce inflammatory cytokines; some improve the skin barrier. For example, tapinarof reduces inflammatory cytokine production; it also reduces oxidative stress and improves skin barrier proteins. So, we're addressing a number of issues in the pathophysiology, such as skin barrier dysfunction and dysregulated immunity.
What clinical trials or studies have been conducted on these emerging therapies, and what are the next steps?
Each of the emerging therapies have to have duplicate studies and registrational studies. For topical roflumilast, we have INTEGUMENT I and INTEGUMENT II. They're basically identical studies to see if you can replicate the results in 2 different locations and different populations.
The results were slightly different. We can't compare one to the other because of the duration of therapy, the patient selection. I think about 30% to 32% of patients achieved IGA [Investigator’s Global Assessment] success with topical roflumilast over 4 weeks.
With tapinarof, we had the 2 studies; the ADORING 1 and ADORING 2 studies. Again, looking at replication of results, with about 40% IGA success over 8 weeks of therapy. So again, greater than placebo, very effective safety, very well tolerated. Really, the only adverse event that we saw in greater than 5% of patients was folliculitis, which we knew from the psoriasis trials. They call it a follicular event; it's not a classic folliculitis that we would see. But overall, well tolerated by patients. This is a population with very sensitive skin who have a lot of burning and stinging with other treatments. So, to have a well-tolerated therapy is really important.
For the lebrikizumab trials, we have the 2 replicated registrational studies, ADvocate 1 and ADvocate 2, which were monotherapy studies. But we also have the ADhere study, which was lebrikizumab vs placebo with the addition of topical corticosteroids. This is done in a large number of patients to show the efficacy and safety. Those results were presented at the meeting.
And then we have nemolizumab, where in Japan it has actually already received approval for pruritis in atopic dermatitis. We don't have it approved here in North America, and the registrational studies have not yet been published. We know that they met their primary end point and that the medication was more effective than the placebo, but we don't have the results for that those trials yet.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More